0 NYSE Companies - October 3, 2024CN to Report Third-Quarter 2024 Financial and Operating Results on October 22, 2024MONTREAL, Oct. 03, 2024 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) will issue its third-quarter 2024 financial and operating […]Read More
0 NYSE Companies - October 3, 2024Le CN divulguera ses résultats financiers et d’exploitation du troisième trimestre de 2024 le 22 octobre 2024MONTRÉAL, 03 oct. 2024 (GLOBE NEWSWIRE) — Le CN (TSX : CNR) (NYSE : CNI) divulguera ses résultats financiers et d’exploitation du troisième […]Read More
0 NYSE Companies - October 3, 2024Minerals Technologies Announces Third Quarter 2024 Conference CallNEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) — Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced today that it […]Read More
0 NYSE Companies - October 3, 2024AMERANT BANK EARNS SPOT ON NEWSWEEK’S 2024 LIST OF AMERICA’S MOST LOVED WORKPLACES FOR THE THIRD CONSECUTIVE YEARMiami, FL, Oct. 03, 2024 (GLOBE NEWSWIRE) — Newsweek recently announced their annual rankings of 2024 America’s Top Most Loved […]Read More
0 NYSE Companies - October 3, 2024Grayscale Investments® Launches Grayscale® Aave TrustSTAMFORD, Conn., Oct. 03, 2024 (GLOBE NEWSWIRE) — Grayscale Investments®, an asset management firm with expertise in crypto investing, offering […]Read More
0 NYSE Companies - October 3, 2024AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of EndometriosisOCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that […]Read More
0 NYSE Companies - October 3, 2024Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative DiseasesNEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) — NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast […]Read More
0 NYSE Companies - October 3, 2024Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar CandidateThe expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024 The […]Read More
0 NYSE Companies - October 3, 2024Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsROCKVILLE, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified […]Read More
0 NYSE Companies - October 3, 2024Costamare Inc. Announces Election of Class II Directors at 2024 Annual Meeting of StockholdersMONACO, Oct. 03, 2024 (GLOBE NEWSWIRE) — Costamare Inc. (the “Company”) (NYSE: CMRE), an international owner and provider of containerships […]Read More